Pantxika Bellecave - Concepedia

Author

Pantxika Bellecave

Centre Hospitalier Universitaire de Bordeaux

Also Known As

ANRS CO3-AQUIVIH-NA-QuAliV, Bellecave, Pantxika, D Bettinger, I Pellegrin, Laure Barthod, P Bellecave, P Trimoulet, P. Bellecave, Pantxika Bellecave, S Reigadas

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Universitaire de Bordeaux Inserm Centre National de la Recherche Scientifique Université de Bordeaux Hôpital Bichat-Claude-Bernard

About

Pantxika Bellecave is an author at Centre Hospitalier Universitaire de Bordeaux specializing in medicine, virology, and hiv.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	273
2	Engineering	2	2	25
3	Natural Sciences	2	2	60
4	Public Health	1	1	22
5	Biochemistry	1	1	13

Pantxika Bellecave

Publications

991

Citations

H-Index

Page 1

	Year	Citations
Hepatitis B and C virus coinfection: A novel model system reveals the absence of direct viral interference # Pantxika Bellecave, Jérôme Gouttenoire, M. Gajer, Hepatology	2009	152
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing Alessandro Cozzi‐Lepri, Marc Noguera-Julián, Francesca Di Giallonardo, Journal of Antimicrobial Chemotherapy	2014	122
Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system† Pantxika Bellecave, Magdalena Filipowicz Sinnreich, Olivier Donzé, Hepatology	2009	118
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis Tom Loosli, Stefanie Hossmann, Suzanne M Ingle, The Lancet HIV Dolutegravir-based Antiretroviral TherapyTreatment And PreventionHuman RetrovirusCollaborative Cohort AnalysisAntiviral Therapy	2023	114
Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure Marie-Anne Vandenhende, Pantxika Bellecave, Patrícia Recordon-Pinson, PLoS ONE	2014	48
Inhibition of Hepatitis C Virus (HCV) RNA Polymerase by DNA Aptamers: Mechanism of Inhibition of In Vitro RNA Synthesis and Effect on HCV-Infected Cells Pantxika Bellecave, Christian Cazenave, Julie Rumi, Antimicrobial Agents and Chemotherapy Viral ReplicationHepatitis C VirusImmunologyMolecular BiologyAntiviral Drug	2008	47
Selection of DNA Aptamers That Bind the RNA-Dependent RNA Polymerase of Hepatitis C Virus and Inhibit Viral RNA Synthesis <i>In Vitro</i> Pantxika Bellecave, Marie‐Line Andréola, Michel Ventura, Oligonucleotides	2003	45
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants Marc Noguera-Julián, Alessandro Cozzi‐Lepri, Francesca Di Giallonardo, Clinical Microbiology and Infection MedicineHuman RetrovirusImmunologyAntiviral Drug DevelopmentResistance Mutation (Virology)	2015	35
Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients Flaminia Olearo, Huyen Nguyen, Fabrice Bonnet, Open Forum Infectious Diseases	2019	35
High Prevalence of Antiretroviral Drug Resistance among HIV-1-Untreated Patients in Guinea-Conakry and in Niger Charlotte Charpentier, Pantxika Bellecave, Mohamed Cissé, Antiviral Therapy	2010	30

Page 1